Market Cap 265.60M P/E - EPS this Y 72.40% Ern Qtrly Grth -
Income -61.5M Forward P/E - EPS next Y 6.30% 50D Avg Chg -25.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book EPS next 5Y - 52W High Chg -53.00%
Recommedations 1.70 Quick Ratio 5.53 Shares Outst. 216.07M 52W Low Chg 146.00%
Insider Own 10.79% ROA -58.07% Shares Float 180.50M Beta -0.20
Inst Own 26.42% ROE -545.95% Short Shares 0 Price 1.06
Gross Margin - Profit Margin - Avg. Volume 8,146,296 Target Price 4.60
Oper. Margin - Earnings Aug 12 Volume 2,729,526 Change -3.64%
9 Meters Biopharma, Inc. News
06:30 AM 9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
04/12/21 9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
04/05/21 9 Meters Biopharma Announces Closing of Offering of Common Stock
03/30/21 9 Meters Biopharma Prices Public Offering of Common Stock
03/30/21 9 Meters Biopharma Announces Proposed Public Offering of Common Stock
03/24/21 Did 9 Meters Biopharma, Inc. (NASDAQ:NMTR) Insiders Buy Up More Shares?
03/22/21 9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020
03/15/21 9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update
03/10/21 9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences
03/09/21 9 Meters Biopharma, Inc. Announces Chief Medical Officer's Presentation at NIH's Accelerating Progress in Celiac Disease Workshop
03/01/21 9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors
02/10/21 9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference
02/04/21 9 Meters Biopharma (NMTR) is Overbought: Is A Drop Coming?
02/03/21 9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities' CEO Strategic Vision Conference Call Series
02/01/21 9 Meters Biopharma, Inc. Announces Research & Development Day on Short Bowel Syndrome
01/05/21 2 “Strong Buy” Penny Stocks That Could Deliver Massive Returns
12/21/20 9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications
12/15/20 9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock
12/11/20 9 Meters Biopharma, Inc. Prices Public Offering of Common Stock

9 Meters Biopharma, Inc., a gastrointestinal platform company, focuses on patients with rare disorders and unmet needs. The company's pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 analogue for SBS; Larazotide, a Phase 3-stage therapeutic in development for celiac disease; and NM-003, a long-acting GLP-2 analogue, which is under orphan indication selection. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.

NMTR Chatroom

User Image RAWG Posted - 46 seconds ago

$NMTR Go check finra numbers 😁 1.1mil of the 2.15mil total volume this past Friday were shares sold short!!!! Let’s get some volume rolling in and squeeeeze this puppy 🤑🤑

User Image zimzy Posted - 8 minutes ago

$NMTR BCRX trending up

User Image elprup Posted - 9 minutes ago

$NMTR not much volume today Wonder if it starts coming in at 3:30...3;45????

User Image elprup Posted - 41 minutes ago

$NMTR that 30,000 @ 1.05 was a nice buy

User Image DuccioB Posted - 1 hour ago

$NMTR According to my calculations I triple in 1 year

User Image colleena Posted - 1 hour ago

$NMTR bought more! I believe in this pipeline and management! Covid delayed trial results- as it did for any pending trial!

User Image FundamentallyShortNMTR Posted - 1 hour ago

$NMTR well well, looking weak for the week. I'm expecting a slide below $ 1. Temperato does not have that market presence to stop a bloodbath. Investors will see through the crap with no catalyst and find a bottom to settle. $ 0.90-ish is a good near-term support. But if you wanna sell house sell car sell body to get a good bet on NMTR, anything under $ 0.60. I expect a rebound at $ 0.60 to $ 0.90 even without any catalyst, simply because investors will buy on the hopes for next year - the Celiac P3 read-out. At the current price, it is still fundamentally overvalued. Cash won't last till the P3 read-out. Expect another round of equity dilution in 2H2021. It needs to do a reverse split for the share price to buffer the fall, or it will be delisted. Sit well for the slide down all your 9 meters of intestines and out.

User Image Trei2334 Posted - 2 hours ago

$NMTR 1.02 touched at 03/31 - 1.42 peak on 04/06 - 1.03 touched today 04/19. Double Bottom? I’m not no expert at reading charts so just a question for someone in here who knows more about reading charts. Appreciate any response😁

User Image Yenni Posted - 2 hours ago

$NMTR Q - Do we dip under a dollar today? If we do, guess I'll have to pick up some more.

User Image sal12 Posted - 2 hours ago

$NMTR adding more ;)

User Image JunChow Posted - 2 hours ago

$NMTR the recent partnerships are definitely a good sign.. it gives some reassurance on the data releases coming out this year ... which in my opion are the real catalysts...

User Image PlanetFitness Posted - 2 hours ago

$NMTR Almost time to buy!! Temperato will not let it go below $1.00 since that’s what he paid in the recent public stock offering, I’m about to get back in and buy when it hits $1.00. He does not want to get back on the Nasdaq delisting list “again”.

User Image PomerGyle Posted - 2 hours ago

$NMTR anyone left in here who has a perspective on the partnership agreement?

User Image BZoo Posted - 3 hours ago

$NMTR At this point I just wish I had more cash to load up.

User Image elprup Posted - 4 hours ago

$NMTR I’m coming duck n roll!!!

User Image Irish_Luck Posted - 4 hours ago

$NMTR mind games. This is going green. Buy buy buy

User Image elprup Posted - 4 hours ago

$NMTR how low will those 1 share premarket buys go 1.07????

User Image elprup Posted - 4 hours ago

$NMTR am I seeing a set up? And then!

User Image MrNiceGuyThatsBroke Posted - 4 hours ago

$NMTR THIS is disgusting

User Image MrNiceGuyThatsBroke Posted - 4 hours ago

$NMTR this

User Image gray8073 Posted - 4 hours ago

$NMTR John and the team are making all the right moves 🤑 Love it! Adding 5k shares here. Plan is to keep accumulating shares every single week in 2021.

User Image elprup Posted - 4 hours ago

$NMTR just remember premarket is for shorts to cover Or is it Any news is progress!!!

User Image SunnySky100 Posted - 4 hours ago

$NMTR Go see CPHI news.

User Image DasFoose Posted - 4 hours ago

$NMTR Morning. Form 8-K announcement of Duke clinical conference. I thought they already filed this or was it a different conference?

User Image Pjw2079 Posted - 5 hours ago

$NMTR DUKE University enters into collaboration study with 9 Meters!!

User Image STCKPRO Posted - 5 hours ago

$NMTR NEW ARTICLE : 9 Meters Biopharma enters collaboration deal for bowel syndrome treatment development

User Image Newsfilter Posted - 5 hours ago

$NMTR 9 Meters Biopharma enters collaboration deal for bowel syndrome treatment development

User Image java4dayz Posted - 5 hours ago

$NMTR Trials will begin they will... shorts will be sad some say... well time to float a stone it is...

User Image elprup Posted - 5 hours ago

$NMTR medical officer of 9 Meters. "NM-002 has shown positive topline data to date with improvements in total stool output and bowel frequency in patients, as well as rapid onset and sustained clinical effects following the first dose. We're excited to have the opportunity to establish this collaboration with such a renowned institute like the DCRI and integrate their expertise and resources as we progress NM-002 through clinical development for patients living with this debilitating disease."

User Image elprup Posted - 6 hours ago

$NMTR uh oh!!! Let the regular hours begin. 🤫

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own
Sirgo Mark A Director Director Sep 14, 8:06 AM Buy 0.64 148,485 95,030 21,485